Amorfix teams with PREVENT for vaccine candidates

Toronto's Amorfix Life Sciences Ltd has granted exclusive worldwide rights for the commercialization of its lead amyotrophic lateral sclerosis (ALS) vaccines to Pan-Provincial Vaccine Enterprise Inc (PREVENT). PREVENT — a Centre of Excellence for Commercialization and Research (CECR) — will take over clinical development of Amorfix's lead vaccine candidates for ALS. The cost-sharing, revenue-sharing agreement will see PREVENT develop vaccine formulations, complete preclinical studies for regulatory approval and conduct clinical testing at their cost. Amorfix retains the rights to develop antibodies and diagnostics for ALS....